Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Research Across America
mi
from
Santa Ana, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Research Across America
mi
from
Santa Ana, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Neurological Research Institute
mi
from
Santa Monica, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Neurological Research Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Redwood Research Medical Group
mi
from
Santa Rosa, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Redwood Research Medical Group
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Alpine Clinical Research Center
mi
from
Boulder, CO
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Alpine Clinical Research Center
mi
from
Boulder, CO
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
IMMUNOe Research Centers
mi
from
Centennial, CO
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
IMMUNOe Research Centers
mi
from
Centennial, CO
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Mile High Research Center
mi
from
Denver, CO
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Mile High Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Chase Medical Research of Greater New Haven
mi
from
Hamden, CT
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Chase Medical Research of Greater New Haven
mi
from
Hamden, CT
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Chase Medical Research, LLC
mi
from
Waterbury, CT
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Chase Medical Research, LLC
mi
from
Waterbury, CT
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Parkinson's Disease and Movement Disorders Center of Boca Raton
mi
from
Boca Raton, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Parkinson's Disease and Movement Disorders Center of Boca Raton
mi
from
Boca Raton, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Meridian Research
mi
from
Brooksville, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Meridian Research
mi
from
Brooksville, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Brain Matters Research
mi
from
Delray Beach, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Brain Matters Research
mi
from
Delray Beach, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
MD Clinical
mi
from
Hallandale Beach, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Alzheimer's Research and Treatment Center
mi
from
Lake Worth, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Alzheimer's Research and Treatment Center
mi
from
Lake Worth, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Miami Jewish Health Systems
mi
from
Miami, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Miami Jewish Health Systems
mi
from
Miami, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Compass Research LLC
mi
from
Orlando, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Roskamp Institute
mi
from
Sarasota, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Roskamp Institute
mi
from
Sarasota, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Axiom Clinical Research of Florida
mi
from
Tampa, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Axiom Clinical Research of Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Stedman Clinical Trials
mi
from
Tampa, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Stedman Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Premiere Research Institute
mi
from
West Palm Beach, FL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Premiere Research Institute
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Neurotrials Research, Inc.
mi
from
Atlanta, GA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Neurotrials Research, Inc.
mi
from
Atlanta, GA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
IU Health Partners Adult Neurology Clinic
mi
from
Indianapolis, IN
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
IU Health Partners Adult Neurology Clinic
mi
from
Indianapolis, IN
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Pharmasite Research
mi
from
Baltimore, MD
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Pharmasite Research
mi
from
Baltimore, MD
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Alzheimers Disease Center, Quincy Medical Center
mi
from
Somerville, MA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Alzheimers Disease Center, Quincy Medical Center
mi
from
Somerville, MA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Springfield Neurology Associates, LLC
mi
from
Springfield, MA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Springfield Neurology Associates, LLC
mi
from
Springfield, MA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Borgess Research Institute
mi
from
Kalamazoo, MI
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Borgess Research Institute
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Cleveland Clinic Lou Ruvo Center for Brain Health
mi
from
Las Vegas, NV
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Cleveland Clinic Lou Ruvo Center for Brain Health
mi
from
Las Vegas, NV
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Comprehensive Clinical Research
mi
from
Berlin, NJ
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Comprehensive Clinical Research
mi
from
Berlin, NJ
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
The Cognitive Research Center of New Jersey
mi
from
Springfield, NJ
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
The Cognitive Research Center of New Jersey
mi
from
Springfield, NJ
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Neurology Specialists of Monmouth County
mi
from
West Long Branch, NJ
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Neurology Specialists of Monmouth County
mi
from
West Long Branch, NJ
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Albuquerque Neuroscience Inc.
mi
from
Albuquerque, NM
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Albuquerque Neuroscience Inc.
mi
from
Albuquerque, NM
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Integrative Clinical Trials, LLC
mi
from
Brooklyn, NY
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Integrative Clinical Trials, LLC
mi
from
Brooklyn, NY
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
SPRI Clinical Trials LLC
mi
from
Brooklyn, NY
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
SPRI Clinical Trials LLC
mi
from
Brooklyn, NY
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
The Litwin-Zucker Research Center
mi
from
Manhasset, NY
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
The Litwin-Zucker Research Center
mi
from
Manhasset, NY
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Parker Jewish Institute Health Care & Rehabilitation
mi
from
New Hyde Park, NY
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Parker Jewish Institute Health Care & Rehabilitation
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
NYU Langone Medical Center Comprehensive Center on Brain Aging
mi
from
New York, NY
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
NYU Langone Medical Center Comprehensive Center on Brain Aging
mi
from
New York, NY
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Eastside Comprehensive Medical Center
mi
from
New York, NY
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Eastside Comprehensive Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Nathan S. Kline Institute Geriatric Psychiatry Program
mi
from
Orangeburg, NY
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Nathan S. Kline Institute Geriatric Psychiatry Program
mi
from
Orangeburg, NY
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
New Hope Clinical Research
mi
from
Charlotte, NC
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
New Hope Clinical Research
mi
from
Charlotte, NC
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Ani Neurology, PLLC dba Alzheimer's Memory Ctr
mi
from
Charlotte, NC
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Ani Neurology, PLLC dba Alzheimer's Memory Ctr
mi
from
Charlotte, NC
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Neuro-Behavioral Clinical Research, Inc.
mi
from
Canton, OH
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Neuro-Behavioral Clinical Research, Inc.
mi
from
Canton, OH
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Valley Medical Research
mi
from
Centerville, OH
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Valley Medical Research
mi
from
Centerville, OH
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
CTI Clinical Research Center
mi
from
Cincinnati, OH
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
CTI Clinical Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Insight Clinical Trials
mi
from
Shaker Heights, OH
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Insight Clinical Trials
mi
from
Shaker Heights, OH
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
IPS Research Company
mi
from
Oklahoma City, OK
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Summit Research Network (Oregon) Inc.
mi
from
Portland, OR
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Summit Research Network (Oregon) Inc.
mi
from
Portland, OR
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Drexel Neurological Associates
mi
from
Philadelphia, PA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Drexel Neurological Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Abington Neurological Associates
mi
from
Willow Grove, PA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Abington Neurological Associates
mi
from
Willow Grove, PA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Medical University of South Carolina
mi
from
Charleston, SC
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials